(NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform’s potential as a next-generation vaccine, today ...
Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback